{"id":"NCT02457546","sponsor":"Ethicon, Inc.","briefTitle":"The EVICEL® Neurosurgery Phase III Study","officialTitle":"A Single-Blinded, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® Fibrin Sealant (Human) Compared to a Hydrogel Sealant as an Adjunct to Sutured Dural Repair","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-01","primaryCompletion":"2017-09-13","completion":"2017-10-12","firstPosted":"2015-05-29","resultsPosted":"2018-12-04","lastUpdate":"2019-01-10"},"enrollment":234,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Cerebrospinal Fluid Leak"],"interventions":[{"type":"BIOLOGICAL","name":"EVICEL Fibrin Sealant","otherNames":["fibrin sealant"]},{"type":"DEVICE","name":"Hydrogel sealant","otherNames":[]}],"arms":[{"label":"EVICEL Fibrin Sealant","type":"EXPERIMENTAL"},{"label":"Hydrogel sealant","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety and efficacy of EVICEL® Fibrin Sealant (Human) for use as an adjunct to sutured dural repair in cranial surgery.","primaryOutcome":{"measure":"Primary Effectiveness Endpoint Success Number of Successes (Subjects That Had no Inter-operative CSF Leak Following Valsalva Maneuver and no CSF Leak or Pseudomeningocele in the Surgical Area During the 30-day Follow-up Period)","timeFrame":"Intraoperatively through 30-day follow-up","effectByArm":[{"arm":"Evicel","deltaMin":22,"sd":null},{"arm":"DuraSeal","deltaMin":23,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":24},"locations":{"siteCount":26,"countries":["United States","Australia","Belgium","Canada","New Zealand","United Kingdom"]},"refs":{"pmids":["25112563"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":114},"commonTop":["Headache","Constipation","Nausea","Procedural pain","Vomiting"]}}